AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia
04 avr. 2019 22h00 HE
|
AnGes MG, Inc.
TOKYO, April 05, 2019 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for treating serious diseases, announced today that they have...
Vasomune Therapeutics and AnGes, Inc. enter into a Multi-Million Dollar Global Co-Development Agreement to Advance an Innovative Platform Targeting Vascular Leakage
31 juil. 2018 07h00 HE
|
AnGes MG, Inc.
TOKYO and TORONTO, July 31, 2018 (GLOBE NEWSWIRE) -- Vasomune Therapeutics (“Vasomune”), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc. (Tokyo,...
AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain
27 févr. 2018 19h31 HE
|
AnGes MG, Inc.
TOKYO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the treatment of the...
AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
22 janv. 2018 22h11 HE
|
AnGes MG, Inc.
TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an...
AnGes Starts Global Phase III Clinical Trials of Collategene(R) for Critical Limb Ischemia
05 oct. 2014 20h20 HE
|
AnGes MG, Inc.
TOKYO, Oct. 6, 2014 (GLOBE NEWSWIRE) -- AnGes MG, Inc. ("AnGes") announces that it has commenced the global phase III clinical trials of Collategene® with the enrollment of patients in the...
AnGes Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma for Exclusive Marketing Rights of Collategene(R) in the United States
23 oct. 2012 23h00 HE
|
AnGes MG, Inc.
TOKYO, Oct. 24, 2012 (GLOBE NEWSWIRE) -- AnGes MG Inc. ("AnGes") announced today that the company has entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation (Head Office:...